

### REMARKS

The current amendment is submitted to amend the original sequence listing, to correct portions of the specification that refer to related applications and the sequence listing and to place the claims in better form for examination.

Please amend claims 1, 3, 6, 12, 18, 19, 26 and 27 cancel claims 20-25 before calculating the filing fee.

On April 10, 1998, in response an Office Action dated March 31, 1998 for the original parent application (Serial No. 08/806,121, filed December 23, 1996 now U. S. Patent No. 6,008,319), Applicants submitted a corrected copy of the Sequence Listing to be substituted for any prior version. Similarly this continuation application includes an amended Sequence Listing (in paper and computer readable forms) to replace the original sequence listing filed with the parent application (Serial No. 08/806,121, filed December 23, 1996 now U. S. Patent No. 6,008,319).

The new Sequence Listing differs from the original Sequence Listing in the following:

- (1) the application serial numbers of the previous related patent applications, which are absent from the original Sequence Listing, are provided in the attached Sequence Listing;
- (2) the sequences are all numbered sequentially starting with the number 1;
- (3) the attached Sequence Listing has an additional entry for amino acid sequence, SEQ ID NO:3; and
- (4) SEQ ID NO:1 is amended to replace the Glu at position 1 of the amino acid sequence with Gln.

Items (1) and (2) do not introduce new matter.

SEQ ID NO:3 of item (3) is provided to facilitate compliance with the Requirements for a Sequence Listing, which require that the sequence listing match the Specification. In some portions of the Specification, the position numbers of various peptide sequences are more readily derived from the full length sequence of IL-2, which is presented in SEQ ID NO:3. The sequence for SEQ ID NO:3 is the same as the sequence for IL-2 disclosed in Taniguchi et al.

(Nature 302: 305-310 (1983)), which is incorporated by reference at page 9, lines 26-28 of the Specification. Accordingly, no new matter is introduced in SEQ ID NO:3.

Item (4) merely corrects a typographical error, wherein Glu was erroneously put in place of Gln. Similarly, Fig 1A has been amended to substitute Gln for Glu in the first amino acid of the peptide sequence presented therein. These corrections are consistent with the initial CAG codon of the corresponding DNA sequence listing (See SEQ ID NO:2) which does for Gln. In addition, the Taniguchi et al. reference discloses Gln at a corresponding position in the full length sequence of IL-2. Accordingly, no new matter is introduced by these corrections.

The specification is also hereby amended at various sites to reflect that certain embodiments of the present invention contain select portions of SEQ ID NO:3. No new matter is introduced by these identifications.

Finally, claim 3 is amended to properly reference amino acid residues 37 to 58 relative to the full length amino acid sequence of IL-2 presented in SEQ ID NO:3. Accordingly, no new matter is introduced.

### CONCLUSION

In view of the above remarks, it is respectfully submitted that the specification, claims and sequence listings are in compliance with requirements for patent applications containing nucleotide sequence and/or amino acid disclosures. In the event that there are any problems which can be expedited by telephone conference, the Examiner is invited to telephone the Applicants' undersigned attorney at the telephone number listed below.

Respectfully submitted,

Date: February 27, 2004



Margaret A. Churchill, Ph.D.  
Registration No. 39,944  
Attorneys for Applicant

Attorney Docket No. 1920-325C1/09801297  
Telephone: (213) 892-9200  
Facsimile: (213) 680-4518